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’INTRODUCTION
G protein-coupled receptor 35 (GPR35) is an orphan G
protein-coupled receptor (GPCR) and is believed to play a role
inhypertension,
1coronary artery disease,
2 asthma,
3 pain,
4,5early
onsetinﬂammatoryboweldisease,
6andcancers.
7Bothkynurenic
acid
8 and 2-acyl lysophosphatidic acid
9 have been postulated
to be natural agonists for GPR35. However, there are only a
handful compounds that have been reported in literature to exhibit
either agonist or antagonist activity on GPR35. These compounds
include zaprinast,
10 pamoic acid,
4 NPPB (5-nitro-2-(3-phenyl-
propylamino)-benzoate),
11 cromolyn and dicumarol,
3 luteolin,
quercetin,andniﬂumicacid,
12allofwhichareGPR35agonists.A
couple of GPR35 antagonists including compound 17 (CID-
2745687, methyl-5-[(tert-butylcarbamothioylhydrazinylidene)-
methyl]-1-(2,4-diﬂuorophenyl)-pyrazole-4-carboxylate) have also
beenreported.
4Thus,identiﬁcationofnovelGPR35ligandswouldbe
beneﬁcial to further elucidate the biology and therapeutic potentials
of GPR35.
Conventional pharmacological assays often measure single
signaling molecules, one at a time, downstream receptor activa-
tion and signaling. Thus, these assays often encounter diﬃcul-
ties to identify ligands for poorly characterized receptors such as
GPR35, whose signaling pathways and biology are largely
unknown. Recently, dynamic mass redistribution (DMR) assays
have been emerging as a powerful tool to delineate receptor
biologyand drug pharmacologyinnativecells.
13 17DMRassays
are enabled by a label-free optical biosensor, which transforms a
cellular response into an integrated and kinetic response, termed
DMR.
18 Because of its pathway-unbiased yet pathway-sensitive
nature in measurement, it has been hypothesized that DMR
assays could oﬀer an unprecedented advantage to discover novel
ligands for receptors, particularly orphan receptors.
19 We set
out to test such a hypothesis by screening an internally made
chemical library against endogenous GPR35 in a native cell line,
HT-29. The library consists of 660 intermediates synthesized in
house, and these intermediates were originally designed for
applications in nonlinear optics
20 and organic ﬁeld-eﬀect tran-
sistors.
21 The chemical library was chosen because (1) these
chemicals were notdesigned for pharmacological applications so
their pharmacological activities were unknown, and (2) some
chemicals contain malononitrile group, similar to tyrphostins.
Certain tyrphostin analogues have been demonstrated to be
GPR35 agonists in our laboratory.
22 Using DMR assays, we had
discovered two novel chemical series, 2-(4-methylfuran-2(5H)-
ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic
acid derivatives, as GPR35 agonists.
’CHEMISTRY
2-(4-Methylfuran-2(5H)-ylidene)malononitrile compounds
were synthesized via the reaction of α-ketols with 2 equiv of
malononitrile under basic conditions. This reaction starts with a
Knoevenagel condensation, followed by the hydroxyl group
attacking one of the nitriles to form an iminolactone intermedi-
ate, which reacts again with malononitrile to result in the ﬁnal
products. The detailed synthesis of compounds 1 (YE120) and
2 8 have been reported previously.
20 Followed the same
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thiophene-2-carboxylic acid derivatives, as GPR35 agonists. Of these, 2-(3-
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(YE120) and 6-bromo-3-methylthieno[3,2-b]thiophene-2-carboxylic acid (YE210)
were found to be the two most potent GPR35 agonists with an EC50 of
32.5 ( 1.7 nM and 63.7 ( 4.1 nM, respectively. Both agonists exhibited better
potency than that of zaprinast, a known GPR35 agonist. DMR antagonist
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procedure,compound9waspreparedfrom3-hydroxy-3-methyl-
butan-2-one.
Thieno[3,2-b]thiophene-2-carboxylic acid derivatives were
synthesized using an aldehyde or ketone-based ring closure
reaction, followed by hydrolysis.
21 Speciﬁcally, compounds 10,
11, 12, and 13 were synthesized through hydrolysis of the
products from a ring closure reaction of ethyl mercaptoacetate
with 3-bromothiophene-2-carbaldehyde, 1-(3-bromothiophen-
2-yl)heptan-1-one, 3-bromo-4-hexylthiophene-2-carbaldehyde,
or 3-bromo-6-methylthieno[3,2-b]thiophene-2-carbaldehyde, re-
spectively. For compounds 16a e, acyl-substituted 3,4-dibro-
mothiophene 14a e was ﬁrst synthesized through a Friedel 
Crafts acylation of 3,4-dibromothiophene (14) with acyl chlor-
ide. The ketone 14a e then underwent a ring closure reaction
with ethyl mercaptoacetate, leading to ethyl 3-alkyl-6-bromo-
thieno[3,2-b]thiophene-2-carboxylate 15a e. After hydrolysis,
compounds 16a e was obtained (Scheme 1). Purity of all the
ﬁnal compounds was found to be greater than 95%, as measured
by reverse phase HPLC on a C18 column.
’RESULTS AND DISCUSSION
Screening GPR35 Agonists with DMR Assays. Because
human colorectal adenocarcinoma cell line HT29 endogenously
expresses functional GPR35,
22 this cell line was chosen to screen
GPR35 agonists. The known GPR35 agonist zaprinast was used
as a reference agonist. Previously, we have showed that zaprinast
resulted in a robust DMR with an EC50 of 0.16 ( 0.02 μM and
internalization of GPR35 in HT29.
22 Compound 17, a known
GPR35antagonist,didnotleadtoanydetectableDMRinHT29,
but dose-dependently blocked the zaprinast DMR with an IC50
of10.5(0.3μM(n=4)(Figure1).Atthehighestdose(64μM),
compound 17 almost completely blocked the zaprinast DMR.
These results suggest that the zaprinast-induced DMR in HT29
is specific to the activation of GPR35.
To screen ligands for GPR35, we used a two-step DMR
desensitization assay. This assay begins with DMR agonist assay
to examine all compounds for their agonist activity in HT29,
followed by DMR desensitization assay to determine the ability
of each compound to block or desensitize the cells responding
to the repeated stimulation with zaprinast at a saturating dose
(1 μM). Both agonist and desensitization assayswere monitored
inrealtimefor1husingEpicsystem.TheEpicsystemisalabel-free
optical biosensor microtiter plate reader tailored to 384-well
resonant waveguide grating biosensor plates. A cellular response
was recorded as a shift in resonant wavelength in picometer
(pm).Theadoptionofsuch atwo-step sequentialassayformatis
based on that (1) DMR assays are noninvasive, thus enabling
Scheme 1
Figure 1. DMR characteristics of known GPR35 ligands in
HT29. (a) Structure of a known GPR35 antagonist compound 17.
(b) The DMR arising from zaprinast (500 nM), the antagonist
compound 17 (32 μM), and zaprinast (500 nM) + compound 17
(32 μM). (c) The dose-dependent blockage of the zaprinast
DMR by compound 17. The data represents mean ( sd (standard
deviation) from two independent measurements, each in duplicate
(n =4 ) .7387 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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multiple step assays, and (2) the cells pretreated with an agonist
become desensitized to the repeated stimulation with a second
agonist when two agonists activate the same receptor.
23 Such a
homologous desensitization is common to almost all GPCR
signaling. The real-time kinetic responsesof allcompoundswere
collected and analyzed.
To identify hits, the amplitudes at 8 min poststimulation of all
compound-induced responses were determined and used as a
basis for hit identiﬁcation in the agonist screen. This is because
zaprinast at a saturating dose (1 μM) led to a maximal response
peaked at about 8 min poststimulation (246 ( 11 pm, n = 32).
Using the compound DMR amplitudes greater than 30% of the
zaprinastresponseasthehitidentiﬁcationcriteria,55hitsintotal
were identiﬁed (Figure2a).
For the desensitization screen, the amplitudes of the zaprinast
DMR during the desensitization step were determined for each
compound. As a positive control, zaprinast in the dimethyl
sulfoxide (DMSO) treated cells gave rise to a DMR with an
amplitude of 238 ( 25 pm (n = 90). Using 3  σ of the positive
control as a basis for hit selection, we found 65 hits that led to a
zaprinastDMRsmallerthan160pm(Figure2b).Thecorrelation
analysis suggests that 53 hits were common between the two
assays (Figure2c).
Structure and activity analysis led to identiﬁcation of 20
compounds that belong to two chemical series, 2-(4-methylfur-
an-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-
carboxylic acid derivatives. Eighteen of these compounds were
further characterized in detail (Figures 3 and 4), given that there
were suﬃcient amounts available for follow-up studies. The
remaining 33 compounds were either orphan in structure or
contain aldehyde or ketone groups, thus excluded in further
studies.
The Agonist Specificity of Compounds to GPR35. Given
thatmany compounds mayexhibit polypharmacologyand DMR
measurement is integrative in nature, a compound-induced
DMRmaycontaincontributionsfrommultipletargets/pathways
withwhichthecompoundintervene.Thus,wefirstexaminedthe
specificity of the 18 compound-induced DMR using DMR
antagonist assays. Each compound was assayed at a dose close
to its respective EC80 or EC100 in the presence of compound 17.
Figure2. ScreeningGPR35agonists.(a)TheDMRamplitudesofcompoundsinthelibraryasafunctionofcompounds.(b)TheDMRsignalsinduced
by zaprinast after the cells were prestimulated with compounds in the library. (c) The correlation between the compound DMR in native cells and the
zaprinast DMR in the compound-pretreated cells.
Figure 3. Structures of 2-(4-methylfuran-2(5H)-ylidene)malononitrile
derivatives identiﬁed as GPR35 agonists.
Figure 4. Structures of thieno[3,2-b]thiophene-2-carboxylic acid deri-
vatives identiﬁed as GPR35 agonists.7388 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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Resultsshowed thatcompound 17dose-dependently attenuated
the DMR arising from all 18 compounds with similar potency
(Table 1). However, compound 17 at 64 μM blocked the DMR
induced by most compounds, except for compounds 5, 7, 8, 11,
and 13, whose DMR were only partially suppressed (Figures 5
and 6). Together with the observed ability of these compounds
to desensitize the cells to the zaprinast stimulation, these results
suggest that the DMR induced by these compounds are mostly
specifictoGPR35,althoughwecannotruleoutthepossibilityof
compounds 5, 7, 8, 11, and 13 to activate endogenous target(s)
besides GPR35.
We further examined the speciﬁcity of these ligands using
DMR agonist assaysafter interference RNA (RNAi) knockdown
of GPR35. Results showed that knockdown of GPR35 using
short hairpin RNA (shRNA) signiﬁcantly suppressed the DMR
signalsinducedby theﬁvecompoundsexamined(Figure.7a e).
Western blot conﬁrmed the eﬃciency of ShRNA knockdown at
least by 60% (Figure 7f). Noticeably, distinct compounds gave
risetodiﬀerentsensitivitytoRNAiknockdown.Thismaybedue
to the diﬀerence in eﬃcacy of these compounds. It is known that
partial agonists are generally more sensitive to the reduction of
functional receptors than full agonists.
24,25
Next, we examined the ability of representative compounds to
cause receptor internalization, a hallmark of the activation of
most GPCRs. We speciﬁcally compared compound 16a with its
analogue,compound15a(Figure8a).Unlike16a,15awasfound
to be inactive in DMR assays (Figure 8b). To study agonist-
induced internalization of endogenous GPR35, the cells were
ﬁrst exposed to an agonist at a given dose for 1 h at 37 C. After
ﬁxationandpermeabilization,thecellswereincubatedwithan
anti-GPR35 antibody (T-14, intracellular domain), followed
by staining with a ﬂuorescently labeled secondary antibody.
Fluorescent confocal imaging showed that GPR35 in the un-
stimulated cells was primarily located at the cell surface (Figure 8c),
and stimulation with 16a caused signiﬁcant internalization of
GPR35(Figure8d).Asexpected,15awasinactiveinthereceptor
internalization assay (Figure 8e).
Last, we examined the ability of these compounds to cause β-
arrestin translocation using the Tango GPR35 arrestin assays.
This assay uses Tango GPR35-bla U2OS cells to detect GPR35
agonist-induced recruitment of TEV protease tagged β-arrestin
molecules to the GPR35-Gal4-VP16 transcription factor fusion
protein linked by a TEV protease cleavage site. The β-arrestin
recruitment leads to release of the transcription factor from the
C-terminusof GPR35, which,inturn, translocatestothenucleus
and activates the expression of β-lactamase. The activity of
β-lactamase is then assayed with the cell permeable LiveBLAzer
ﬂuorescence resonance energy transfer (FRET) B/G substrate.
Results showed that zaprinast led to a dose-dependent response
inTangoGPR35-blaU2OScellswithasigniﬁcantlyright-shifted
potency, EC50 of 4.20 ( 0.25 μM( n = 4) (Figure9; Table 1).
Among all the compounds examined, compound 1, 3, 16a, and
16cgaverisetodose-dependentandsaturableresponsesbutwith
distinct potency and eﬃcacy (Figure 9; Table 1). Compounds 7,
9, 10, 11, 12, 13, and 16b also led to detectable responses
(Figure9 and Table 1). However, 2, 4, 5, 6, 8, 15a, 16d, and 16e
all at a dose up to 128 μM were inactive in this assay. These
results suggest that 16a is a full agonist in the arrestin transloca-
tion assay, while1,3,7, 9,10,11, 12,13,16b, and16care partial
agonists. However, considering the common right-shifted
potency of GPR35 agonists obtained using the Tango assay,
wecannotruleoutthepossibilitythattheothercompoundsmay
also be active but with much lower potency. Collectively, we
Table 1. Compounds, Their Eﬃcacy in DMR Assays or Tango Assays Relative to Zaprinast, and Potency (EC50 to Trigger DMR,
IC50toDesensitizeCellsuponRepeatedStimulationwith1μMZaprinast,IC50oftheKnownGPR35AntagonistCompound17to
Block the Agonist-Induced DMR, and EC50 to Trigger β-Arrestin Translocation in Tango Assays)
DMR assays Tango assays
compd % zaprinast EC50 (μM) desensitization IC50 (μM) Antagonist IC50 (μM) % zaprinast EC50 (μM)
zaprinast 100 ( 5 0.16 ( 0.02 1.22 ( 0.10 10.5 ( 0.3 100 ( 7 4.20 ( 0.25
1 97 ( 6 0.032 ( 0.002 0.060 ( 0.007 12.8 ( 0.8 29 ( 5 10.2 ( 0.91
2 84 ( 9 3.35 ( 0.25 4.48 ( 0.36 14.7 ( 1.2 inactive inactive
3 99 ( 4 3.50 ( 0.21 1.94 ( 0.23 20.9 ( 1.5 14 ( 5 >50
4 90 ( 6 6.6 ( 0.5 21.6 ( 3.1 5.1 ( 0.7 ND ND
5 90 ( 5 11.1 ( 1.7 10.3 ( 0.9 11.4 ( 1.3 ND ND
6 100 ( 4 15.3 ( 2.1 6.4 ( 1.1 13.3 ( 0.9 inactive inactive
7 106 ( 9 45.9 ( 4.9 16.4 ( 1.5 22.8 ( 1.7 weak >50
8 99 ( 7 53.9 ( 5.4 48.9 ( 3.7 8.2 ( 1.1 inactive inactive
9 87 ( 5 17.1 ( 2.2 12.1 ( 1.6 7.9 ( 0.5 weak >50
10 81 ( 4 42.4 ( 3.7 57.0 ( 4.1 6.3 ( 0.6 inactive inactive
11 99 ( 4 3.44 ( 0.17 1.49 ( 0.12 27.6 ( 3.5 20 ( 4 >50
12 103 ( 3 9.4 ( 0.7 4.69 ( 0.09 16.0 ( 2.1 9 ( 3 >50
13 118 ( 3 6.0 ( 1.2 6.07 ( 0.14 18.2 ( 1.7 19 ( 4 >50
16a 105 ( 3 0.064 ( 0.004 0.11 ( 0.01 6.9 ( 0.5 104 ( 5 15.0 ( 1.2
16b 103 ( 7 1.46 ( 0.17 1.05 ( 0.07 25.8 ( 1.9 8 ( 3 >50
16c 87 ( 9 1.89 ( 0.23 0.57 ( 0.05 23.8 ( 2.4 55 ( 6 22.7 ( 3.1
16d 77 ( 7 2.31 ( 0.35 1.87 ( 0.14 24.8 ( 1.5 inactive inactive
16e 81 ( 11 4.56 ( 0.41 5.92 ( 0.67 20.2 ( 1.4 inactive inactive
15a inactive NA NA NA inactive inactive7389 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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demonstrated that the two chemical series compounds are
GPR35 agonists.
Structure and Activity Analysis. To further examine struc-
ture and activity analysis, we determined the potency of all 18
compounds to trigger DMR signals in HT29 cells using DMR
assays.Theresultsshowedthatallcompoundsgaverisetoaclear
dose-dependent response (Figure10). All compounds led to a
saturable response at the dose ranges examined. However, there
are significant differences in potency, efficacy, and DMR char-
acteristics of these compounds (Table 1, Figures 5 and 6).
The DMR desensitization assays showed that all compounds
also dose-dependently desensitized the cells to the repeated
stimulation with 1 μM zaprinast, and the rank order of their
apparent IC50 values to desensitize the cells is similar to that of
their respective EC50 values (Figure11). This suggests that all
compounds activate GPR35 as zaprinast does. Of these, 2-(3-
cyano-5-(3,4-dichlorophenyl)-4,5-dimethylfuran-2(5H)-ylide-
ne)malononitrile(1,YE120) and 6-bromo-3-methylthieno[3,2-b]-
thiophene-2-carboxylic acid (16a, YE210)
26 were the two most
potent agonists, and their respective EC50 was 32.5 ( 1.7 nM
(n=4)and63.7(4.1nM(n=4),bothofwhicharemorepotent
than zaprinast (163 ( 19 nM, n = 4).
With the identiﬁcation of potent compound 16a, we further
examined the functional groups critical to its agonist activity.
Changing the carboxylic acid to an ethyl carboxylate led to
compound 15a (Figure 8a). Compound 15a was found to be
inactive in HT-29 in DMR agonist assay (Figure 8b) and also
unabletotriggerreceptorinternalization(Figure8e).Removalof
the bromo group at C6 and replacing the methyl group with
hexyl group led to compound 11, which exhibited about 54-fold
decrease in potency (Table 1). Removal of both bromo and
methyl groups resulted in compound 10, which decreased its
potency by over 600-fold (Table 1). Replacing the methyl group
with a long-chained n-alkyl group resulted in compound 16b e
a n da l s or e d u c e db o t hp o t e n c ya n de ﬃcacy. Further, convert-
ing the backbone from thieno[3,2-b]thiophene into dithieno-
[3,2-b:20,30-d]thiophene led to compound 13, which also exhibited
alower potency.Theseresultsclearly reveal theimportance of3-
and 6-position groups, carboxylic acid, and the size of backbone
for its potency and agonist activity of thieno[3,2-b]thiophene-2-
carboxylic acid derivatives. Compound 16a is a full agonist in
both DMR and Tango assays, while 11, 12, 13, 16b, and 16c are
partial agonists in Tango assays.
Next, we examined the structure and activity relationship of
2-(4-methylfuran-2(5H)-ylidene)malononitrile derivatives for
their agonist activity. Adding a chloro group at the 2-position of
thephenylgroupofcompound1leadsto5,whichexhibited350-
fold decrease in potency to trigger DMR signal and became
inactiveinTangoassay.Replacing3,4-dichlorophenylgroupwith
pentaﬂuorophenyl group (2)o r2 , 4 - b i ﬂuorophenyl group (8)
or 40-n-butylphenyl group (6)o rm e t h y lg r o u p( 9)a l ll e dt o
signiﬁcantlostinitspotencytotriggerDMRaswellasitseﬃcacy
to trigger β-arrestin translocation. Replacing 3,4-dichlorophenyl
and methyl groups at the 5-position of its furan ring with phenyl
and spiro groups leads to compound 3, which exhibited lower
potency in both DMR and Tango assays. These results suggest
Figure5. TheDMRcharacteristics of2-(4-methylfuran-2(5H)-ylidene)malononitrile derivatives.(a i)Compound1(250nM),2(8μM),3(4μM),
4 (8 μM), 5 (16 μM), 6 (16 μM), 7 (32 μM), 8 (32 μM), and 9 (32 μM), respectively. Each compound-induced DMR (Control) was compared to its
corresponding DMR in the presence of 32 μM 17, the known GPR35 antagonist (Antagonist). The data represents mean ( sd from two independent
measurements, each with four replicates (n = 8).7390 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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Figure 6. The DMR characteristics of thieno[3,2-b]thiophene-2-carboxylic acid derivatives. (a i) Compound 10 (32 μM), 11 (16 μM), 12 (16 μM),
13 (16 μM), 16a (250 nM), 16b (8 μM), 16c (8 μM), 16d (8 μM), and 16e (8 μM), respectively. Each compound induced DMR (Control) was
comparedtoitscorrespondingDMRinthepresenceof32μMcompound17,theknownGPR35antagonist(Antagonist).Thedatarepresentsmean(
sd from two independent measurements, each with four replicates (n = 8).
Figure 7. shRNA knockdown of GPR35 signiﬁcantly attenuated the DMR induced by GPR35 agonists identiﬁed. (a) Zaprinast, (b) 1, (c) 9, (d) 16a,
and(e)13.Allcompoundswereassayedat10μM.Thedatarepresentsmean(sdfromfourreplicates(n=4)forallcompounds.Themocktransfection
was used the positive control. (f) Western blotting showed the knockdown of GPR35 proteins by the shRNA.7391 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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that the functional groups at the 5-position of its furan ring is
critical to the agonist activity of compound 1.
Finally, we examined the ligand-directed functional selectivity
of GPR35 agonists. The known GPR35 agonist zaprinast were
found to be active in both DMR and Tango assays, with an EC50
of0.16and1.47μM,respectively.Comparedtozaprinast,both1
and 16a are more potent to trigger DMR signal (EC50 of 0.032
and0.064μM,respectively)butlesspotenttoresultinβ-arrestin
Figure 9. Dose-dependent responses of GPR35 ligands as measured using Tango β-arrestin translocation gene reporter assays. The coumarin to
ﬂuorescein ratio was plotted as a function of ligand doses. Zaprinast was included as a positive control. The data represents mean ( sd from two
independent measurements, each in duplicate (n = 4).
Figure8. Compound15awasunabletoactivateGPR35.(a)Structuresof15aand16a.(b)Thenet-zeroDMRinducedby15a,incomparisonwiththat
by 16a. The data represents mean ( sd from four replicates (n = 4). (c e) Representative ﬂuorescence images of HT-29 under diﬀerent conditions:
unstimulated(c),stimulatedwith1μM16a(d),orstimulatedwith10μMcompound15a(e).Theimageswereobtainedaftercompoundtreatmentfor
1 h, permeabilized, and stained with anti-GPR35, followed by ﬂuorescent secondary antibody. Red: GPR35 stains. Blue: nuclei stains with DAPI.7392 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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translocation (EC50 of 10.2 and 15.0 μM, respectively). Further,
comparedtozaprinast,16aisalsoafullagonistinbothDMRand
Tango assays, but 1 is only a full agonist to trigger DMR but a
partial agonist to result in β-arrestin translocation. Such an assay
Figure 10. Representative DMR signals of GPR35 agonists identiﬁed. (a) The dose-dependent DMR induced by 1, (b) the dose-dependent DMR
induced by 16a, (c) the amplitudes of the DMR induced by 2-(4-methylfuran-2(5H)-ylidene)malononitrile derivatives as a function of doses, and (d)
the amplitudes of the DMR induced by thieno[3,2-b]thiophene-2-carboxylic acid derivatives as a function of doses.
Figure 11. The dose-dependent desensitization by GPR35 agonists identiﬁed to the repeated stimulation with zaprinast (1 μM). (a,b) Real-time
zaprinast DMR after pretreatment with 1 (a) and 2 (b), respectively, and (c) and (d) dose-dependent desensitization by thieno[3,2-b]thiophene-2-
carboxylic acid derivatives (c) and thieno[3,2-b]thiophene-2-carboxylic acid derivatives (d), respectively.7393 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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readout-dependent potency and eﬃcacy suggests that diﬀerent
GPR35 agonists display ligand-directed functional selectivity.
27
’CONCLUSIONS
We have screened an internally made compound library
against a poorly characterized orphan receptor GPR35 using
DMR assays and have identiﬁed two chemical series, 2-(4-methyl-
furan-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-
carboxylic acid derivatives, which represent novel classes of
GPR35 agonists. The agonist activity of 18 compounds was
found to be speciﬁc to GPR35 based on DMR antagonist assays
using a known GPR35 antagonist compound 17, DMR desensi-
tization assays against zaprinast, receptor internalization, and
β-arrestin translocation assays. The structure activity relation-
shipsoftheseligandsasGPR35agonistshavebeenalsoexplored.
Notably, the carboxylic acid group of thieno[3,2-b]thiophene-2-
carboxylic acid derivatives was found to be critical to activate
GPR35. Because malononitrile is relatively acidic under physio-
logicalconditions,itmayalsobeimportanttotheagonistactivity
of 2-(4-methylfuran-2(5H)-ylidene)malononitrile derivatives. This
study expands current pharmacological tools to characterize the
biology and functions of GPR35 and presents a good starting
point to design and optimize new GPR35 ligands.
’EXPERIMENTAL SECTION
Chemistry. All reactions were performed in reagent grade solvent.
The progress of the reactions was checked by GC/MS (Agilent 7820A
GC/5875 MS) and analytical thin-layer chromatography (TLC). Plates
were visualized first with UV illumination, followed by charring with
phosphomolybdic acid. Flash column chromatography was performed
using silica gel (200 300 mesh).
1H NMR spectra were recorded by
Bruker-300 MHz NMR spectrometers in the indicated deuterated
solvents and are reported in parts per million (ppm) on the δ scale
relative to residual CD2Cl2 (δ 5.32), THF-D7H (δ 3.58, 1.73), and
acetone-d6 (δ 2.05). Splitting patterns are provided as apparent multi-
plicities: s (singlet), d (doublet), t (triplet), m (multiplet), and br
(broad).
13C NMR spectra were recorded in the indicated deuterated
solvents by Bruker-75 MHz and are reported in parts per million (ppm)
on the δ s c a l er e l a t i v et or e s i d u a lC D 2Cl2 (δ 53.8) and DMSO-d6
(δ 39.5). High-resolution mass spectra (HRMS) were recorded on an
Agilent 1100 mass spectrometer using Matrix-assisted laser desorption
ionization (MALDI) or electron ionization (EI). We chose the negative
ion mode of operation for EI mass spectroscopy characterization of
fused thiophene molecules containing an acidic side group, which
resulted in the generation ofthe deprotonated molecular ion from these
molecules. The purity determination of all reported compounds was
performed with an Agilent 1100 equipped with Waters columns
(Atlantis T3, 2.1 mm   50 mm, 3 μm; or Atlantis dC18, 2.1 mm  
50 mm, 5 μm) eluted for >10 min with a gradient mixture of
H2O acetonitrile with formic or trifluoroacetic acid at wavelengths of
220, 254, and 280 nm. All compounds analyzed were >95% pure.
Synthesis and characterization of compound 1 (2-(3-cyano-5-(3,4-
dichlorophenyl)-4,5-dimethylfuran-2(5H)-ylidene)malononitrile, 2 2-
(3-cyano-4,5-dimethyl-5-(perfluorophenyl)furan-2(5H)-ylidene)ma lo-
nonitrile), 3 (2-(3-cyano-4-methyl-5-phenyl-5-(trifluoromethyl)furan-
2(5H)-ylidene)malononitrile), 4 (2-(40-cyano-30-methyl-50H-spiro-
[fluorene-9,20-furan]-50-ylidene)malononitrile), 5 (2-(3-cyano-4,5-di-
methyl-5-(2,3,4-trichlorophenyl)furan-2(5H)-ylidene)malononitrile), 6
(2-(5-(4-butylphenyl)-3-cyano-4,5-dimethylfuran-2(5H)-ylidene)malono-
nitrile), 7 (2-(3-cyano-4-methyl-1-oxaspiro[4.5]dec-3-en-2-ylidene)-
malononitrile), and 8 (2-(3-cyano-5-(2,4-difluorophenyl)-4,5-di-
methylfuran-2(5H)-ylidene)malononitrile) were reported previously.
20
NMR and mass spectra of other compounds were included in Support-
ing Information.
2-(3-Cyano-4,5,5-trimethylfuran-2(5H)-ylidene)malononitrile (9).
3-Hydroxy-3-methylbutan-2-one (1.0 equiv), malononitrile (3.2 equiv),
and magnesium ethoxide (0.01 equiv) in ethanol were mixed and re-
fluxed overnight. The solution was concentrated by removing the
majority of the THF on a rotary evaporator under aspirator vacuum.
The remaining residue was taken up in methylene chloride and
washedwithbrine(2times)andthenDIwater(2times).Theorganic
layer was dried over anhydrous MgSO4 a n df i l t e r e da n dt h es o l v e n t
removed.Thecrudeproductwasrecrystallizedfromdenaturedalcohol
to afford 9. Yield: 29%.
1H NMR (300 MHz, acetone-d6): δ 2.36
(s,3H),1.63(s,6H).HRMS(EI)forC11H9N3O:calcd,199.07;found,
199.07 [M].
Thieno[3,2-b]thiophene-2-carboxylic Acid (10). 3-Bromothio-
phene-2-carbaldehyde (1.0 equiv) was mixed with K2CO3 (4.0 equiv)
in dimethylformamide (DMF) in a three-neck flask equipped with
a condenser and addition funnel. After ethyl mercaptoacetate (1.0
equiv) was added dropwise at 60 70 C, the mixture was heated
overnight until no starting materials were detected by GC/MS.
The mixture then was poured into water and the product was
extracted by diethyl ether. The organic phase was washed with brine
anddriedoveranhydrousMgSO4.Theresultantbrownishcrudeethyl
thieno[3,2-b]thiophene-2-carboxylate was obtained and found to be pure
enough for the next reaction. After dissolved in a mixture of THF
andmethanol (1:1)inthepresenceof1M LiOHandrefluxedover-
night, the mixture was poured into concentrated hydrochloric acid.
The acid mixture was then diluted with water. Solid was filtrated,
washed with water and methanol, and purified with flash column
chromatography to provide the light-yellow solid of compound 10
(89% overall yield).
1H NMR (300 MHz, acetone-d6): δ 8.12
(s, 1H), 7.88 (d, 1H), 7.48 (d, 1H). HRMS (EI) for C7H4O2S2:
calcd, 183.96; found, 138.97 [M   COOH].
3-Hexylthieno[3,2-b]thiophene-2-carboxylic Acid (11). 1-(3-Bro-
mothiophen-2-yl)heptan-1-one (1.0 equiv) was mixed with K2CO3
(4.0 equiv) in DMF in a three-neck flask equipped with a condenser
and addition funnel. After ethyl mercaptoacetate (1.0 equiv) was added
dropwise at 60 70 C, the mixture was heated at 60 70 C overnight
until no starting materials was detected by GC/MS. The mixture was
thenpouredintowaterandextractedbydiethylether.Theorganicphase
was washed with brine and dried over anhydrous MgSO4. The residue
was the brownish crude ethyl 3-hexylthieno[3,2-b]thiophene-2-carbox-
ylate, which was directly dissolved into a mixture of THF and methanol
containing 1 M LiOH and refluxed overnight. The mixture was poured
into concentrated hydrochloric acid. The acid mixture was then diluted
withwater.Solid wasfiltrated,washedwith waterandthenmethanol,and
purified by flash column chromatograph to provide the light-yellow solid
ofcompound11(83%overallyield).
1HNMR(300MHz,TDF):δ11.48
(br, 1H), 7.68 (d, 1H), 7.31 (d, 1H), 3.19 (t, 2H), 1.42 1.31 (m, 8H),
0.89 (t, 3H). The small peaks at 3.73 (s), and 2.80 (t) indicated that
compound 11 was contaminated with 3 6% byproduct.
13C NMR (75
MHz, CD2Cl2): 145.6, 142.4, 132.3, 126.9, 120.5, 32.0, 29.9, 29.7, 23.0,
14.2.HRMS(EI)forC13H16O2S2:calcd,268.06;found,267.13[M H].
6-Hexylthieno[3,2-b]thiophene-2-carboxylic Acid (12). 3-Bromo-4-
hexylthiophene-2-carbaldehyde (1.0 equiv) was mixed with K2CO3
(1.5 equiv) in DMF in a three-neck flask equipped with a condenser and
an addition funnel. After ethyl mercaptoacetate (0.5 equiv) was added
dropwiseatroomtemperature,themixturewasstirredatroomtempera-
tureovernightuntilnostartingmaterialsweredetectedbyGC/MS.The
mixture was then poured into water and extracted by ethyl acetate.
Organic extracts were washed by brine and dried over MgSO4 to yield
the brownish crude ethyl 6-hexylthieno[3,2-b]thiophene-2-carboxy-
late, which was then dissolved into a mixture of THF and 1 M LiOH.
This mixture was refluxed overnight and poured into concentrated7394 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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hydrochloric acid. The acid mixture was then diluted with water. Solid
was filtrated andwashed withwater. Theresiduewas recrystallized from
hexane to provide the light-yellow solid of 12 (46% overall yield).
1H
NMR (300 MHz, CD2Cl2): δ 8.10 (s, 1H), 7.50 (s, 1H), 2.78 (t, 2H),
1.72 1.68 (m, 2H), 1.42 1.36 (m, 6H), 0.88 (t, 3H). HRMS (EI) for
C13H16O2S2: calcd, 268.06; found, 267.13 [M   H].
5-Methyldithieno[3,2-b:20,30-d]thiophene-2-carboxylicAcid(13).3-
Bromo-6-methylthieno[3,2-b]thiophene-2-carbaldehyde (1.0 equiv) was
reactedwithethylmercaptoacetate(1.0equiv)inthepresenceofK2CO3
(4.0 equiv) in DMF to provide the yellow solid ethyl 5-methyldithieno-
[3,2-b:20,30-d]thiophene-2-carboxylate, which was then (0.16 mol) dis-
solved in LiOH (10% in water), THF, and methanol (2:6:1). The mixture
wasrefluxedovernightandpouredintoconcentratedhydrochloricacid.The
residue was purified by flash column chromatography to provide the light-
yellow powder 13 (73% overall yield); mp 289 290 C.
1HN M R( 3 0 0
MHz,DMSO-d6):δ8.19(s,1H),7.49(s,1H),2.55(s,3H).
1HNMR(300
MHz, TDF): δ 8.04 (s, 1H), 7.25 (s, 1H), 2.37 (s, 3H).
13C NMR (75
MHz, DMSO-d6): 163.1, 145.3, 140.0, 135.2, 134.1, 130.5, 129.2, 14.1.
HRMS (EI) for C10H6O2S3: calcd, 253.95; found, 253.04 [M   H].
General Procedure for the Synthesis of 3-Alkyl-thieno[3,2-b]thio-
phene-2-carboxylicAcid(16a e).Thesecompoundsweresynthesized
using the protocol shown in Scheme 1.
To a mixture of 3,4-dibromothiophene 14 (1.0 equiv) and AlCl3
(2.0equiv)inCH2Cl2at0C,acetylchloride(1.0equiv)wasaddeddropwise
under a nitrogen stream. This mixture was stirred for 2 3 h until no
starting materials could be detected by GC/MS. The mixture was then
poured into 6 M HCl and the organic was extracted with CH2Cl2 and
dried over anhydrous MgSO4. The mixture was then poured into 6 M HCl
and the organic was extracted with CH2Cl2 and dried over anhydrous
MgSO4. Evaporation of the solvent gave the crude acetyl-substituted 3,4-
dibromothiophene 14a e.
The crude acetyl-substituted 3,4-dibromothiophene (14a e)
(1.0 equiv) was mixed with K2CO3 (5.0 equiv) and DMF in a three-
neck ﬂask equipped with a condenser and addition funnel. After ethyl
mercaptoacetate (1.0 equiv) was added dropwise at 60 70 C, a catalytic
amount of 18-crown-6 was added. The mixture was heated at 60 70 C
overnightuntilnostartingmaterialsweredetectedbyGC/MS.Themixture
was then poured into water.
Solid was ﬁltrated, washed with water and then methanol, and
aﬀorded crude ethyl 3-alkyl-6-bromothieno[3,2-b]thiophene-2-carbox-
ylate 15a e.
Ethyl 3-alkyl-6-bromothieno[3,2-b]thiophene-2-carboxylate (15a e)
(0.16 mol) dissolved in LiOH (10% in water), THF, and methanol
(2:6:1). The mixture was reﬂuxed overnight until no starting materials
weredetectedbyTLC.THFwasevaporated,andtheresiduewasacidiﬁed
with 6N HCl to aﬀord 3-alkyl-thieno[3,2-b]thiophene-2-carboxylic acid
16a e.
1-(3,4-Dibromothiophen-2-yl)ethanone (14a). Crude yields: 95%
mp 75 78 C.
1H NMR (300 MHz, CD2Cl2): δ 7.67 (s, 1H), 2.69 (s,
3H).
13C NMR (75 MHz, CD2Cl2): 189.6, 140.6, 130.2, 118.0, 117.3,
29.7.HRMS(EI)forC6H4Br2OS:calcd,281.83found,280.97[M H]
and 282.91 [M   H + 2]. The dual molecular ion species are chara-
cteristic of a single bromide due to the presence of two isotopes of
bromide.
Ethyl 6-Bromo-3-methylthieno[3,2-b]thiophene-2-carboxylate
(15a). 15awas purifiedwith flashcolumnchromatography. Yields:95%
mp 91 92 C.
1H NMR (300 MHz, CD2Cl2): δ 7.48 (s, 1H), 4.36 (q,
2H), 2.63 (s, 3H), 1.38 (t, 3H).
13C NMR (75 MHz, CD2Cl2): 163.2,
141.7, 141.4, 138.9, 129.5, 127.9, 103.5, 61.6, 14.9. HRMS (EI) for
C10H7BrO2S2: calcd, 303.92; found, 303.20 [M   H] and 305.13
[M   H + 2].
6-Bromo-3-methylthieno[3,2-b]thiophene-2-carboxylic Acid (16a).
Overall yield:86%.mp280 282 C.
1H NMR(300MHz,TDF):δ 7.68
(s,1H),2.69(s,3H).
1HNMR(300MHz,CD2Cl2):δ7.67(s,1H),2.69
(s, 3H).
1H NMR (300 MHz, DMSO-d6): δ 8.07 (s, 1H), 2.60 (s, 3H).
13CNMR(75MHz,DMSO-d6):163.6,140.7,140.1,137.7,129.7,129.2,
102.1, 14.2. HRMS (EI) for C8H5BrO2S2: calcd, 275.89; found, 275.06
[M   H], 276.92 [M   H + 2], due to the presence of two isotopes of
bromide.
6-Bromo-3-octylthieno[3,2-b]thiophene-2-carboxylic Acid (16b).
Overall yield: 86%.
1H NMR (300 MHz, TDF): δ 11.67 (br, 1H),
7.79 (s, 1H), 3.18 (t, 2H), 1.45 1.33 (m, 12H), 0.92 (t, 3H). HRMS
(EI) for C15H19BrO2S2: calcd, 374.00; found, 373.07 [M   H], 375.00
[M   H+2 ]
6-Bromo-3-undecylthieno[3,2-b]thiophene-2-carboxylic Acid (16c).
Overallyield:56%.
1HNMR(300MHz,TDF):δ11.61(br,1H),7.73(s,
1H), 3.18 (t, 2H), 1.35 1.28 (m, 16H), 0.88 (t, 3H). HRMS (EI) for
C18H25BrO2S2:calcd,416.05;found,415.15[M H],417.01[M H+2].
6-Bromo-3-tridecylthieno[3,2-b]thiophene-2-carboxylic Acid (16d).
Overallyield:46%.
1HNMR(300MHz,CD2Cl2):δ7.55(s,1H),3.17(t,
2H), 1.78 1.75 (t, 2H), 1.42 1.28 (m, 22H), 0.87 (t, 3H).
1HN M R
(300MHz,TDF):δ11.58(br,1H),7.72(s,1H),3.18(t,2H),1.35 1.22
(m, 22H), 0.88 (t, 3H). HRMS (EI) for C20H29BrO2S2: calcd, 444.08;
found, 443.09 [M   H], 445.02 [M   H+2 ]
6-Bromo-3-pentadecylthieno[3,2-b]thiophene-2-carboxylic Acid
(16e). Overall yield 59%.
1H NMR (300 MHz, TDF): δ 11.63 (br,
1H), 7.72 (s, 1H), 3.18 (t, 2H), 1.35 1.22 (m, 25H), 0.88 (t, 4H).
HRMS (EI) for C22H33BrO2S2: calcd, 472.11; found, 471.27 [M   H],
473.13 [M   H+2 ] .
Compounds and Reagents. Zaprinast was obtained from Enzo
Life Sciences (Plymouth Meeting, PA). Compound 17 was obtained
from Ryan Scientific, Inc. (Mt. Pleasant, SC). Epic 384-well biosensor
microplates were obtained from Corning Inc. (Corning, NY, USA).
Cell Culture. Human colorectal adenocarcinoma HT-29 was ob-
tained from American Type Cell Culture (Manassas, VA, USA). The
cellswereculturedinMcCoy’s5aMediumModifiedsupplementedwith
10% fetal bovine serum, 4.5 g/L glucose, 2 mM glutamine, and anti-
biotics at 37 C under air/5% CO2. Tango GPR35-bla U2OS cells were
purchased from Invitrogen. The cells were cultured according to the
protocols recommended by the supplier. Briefly, the cells were passed
using McCoy’s 5A medium (Invitrogen 16600 082) supplemented
with 10% dialyzed fetal bovine serum, 0.1 μM NEAA, 25 μM Hepes
(pH 7.3), 1 mM sodium pyruvate, 100 U/mL penicillin, 100 μg/mL
streptomycin, 200 μg/mL zeocin, 50 μg/mL hygromycin, and
100 μg/mL geneticin in a humidified 37 C/5% CO2 incubator.
DMR Assays Using Epic System. All DMR assays were per-
formed using Epic system (Corning Inc., Corning, NY). Epic is a
wavelength interrogation reader system tailored for resonant waveguide
grating biosensors in microtiter plates. This system consists of a
temperature-control unit (26 C), an optical detection unit, and an
on-board liquid handling unit with robotics. The detection unit is
centered on integrated fiber optics and enables kinetic measures of
cellular responses with a time interval of ∼15 s. Cells were directly
seeded in Epic plates and cultured overnight to form a confluent
monolayer in the cell culture medium. After being washed twice, the
cells were maintained with Hank’s Balanced Salt Solution and further
incubated inside the system for 1 h. For agonist screen, a 2 min baseline
was then established. Immediately after the compound addition using
the onboard liquid handler, the cellular responses were recorded. For
desensitization assays, cells were initially treated with compounds for
1 h, followed by stimulation with zaprinast at a fixed dose. The cellular
responses were recorded throughout the assays. All EC50 or IC50
described in the main text were calculated based on the amplitudes of
DMR signals at 8 min post agonist stimulation. Because all GPR35
agonists led to a sustained positive-DMR (P-DMR) signal, the ampli-
tudes at 50 min post stimulation were also used to determine kinetics
dependent potency and efficacy of all ligands.7395 dx.doi.org/10.1021/jm200999f |J. Med. Chem. 2011, 54, 7385–7396
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FortheRNAiknockdownofGPR35,HT29cellswereseededonEpic
plates at 5000 cells/well and allowed to incubate at 37 Cf o r2 4h(d a y1 ).
On day 2, cells were washed with fresh growth media of HT29 once,
then leave cells with 30 μL/well of growth media (McCoy’s 5a media,
10  PBS, 1  Pen/Strap, all from Invitrogen, San Diego, CA, USA).
Short hairpin RNA (shRNA) constructs for targeting human GPR35
mRNA were obtained from Origene (Rockville, MD, USA) and are in
pGFP-V-RS vector which express green ﬂuorescent protein (GFP) for
easy determination of transfection eﬃciency. Transient transfection of
shRNA plasmids and control plasmids was performed using Eﬀectene
transfection system from Qiagen according to manufacturer’s instruc-
tions (Qiagen, Valencia, CA, USA). Brieﬂy, 0.05 μg of plasmid DNA
were mixed with Enhancer and Buﬀer EC for 20 min at room
temperature followed by the addition of diluted Eﬀectene solution.
Theﬁnalmixturewereincubatedatroomtemperaturefor30minbefore
being dispensed to each 384-well for 20 μL/well. The Epic plates
containing HT29 cells and shRNA constructs in transfection reagents
were centrifuged at 500 rpm for 1 min and put back in 37 C for
incubation. On day 3, media of HT29 cells were replaced with fresh
growth media at 40 μL/well and cells were allowed to incubate for
another 24 h. On day 4, about 48 h post-transfection, HT29 cells were
subjected to DMR assays in agonist mode as described above. Zaprinast
was obtained from Tocris Chemical Co. (St. Louis, MO, USA). All
compounds were stocked in DMSO at 10 mM and were diluted directly
in the assay buﬀer (1  Hanks’ Balanced Salt Buﬀer, 20 mM Hepes, pH
7.1; HBSS) to the indicated concentrations. Epic 384-well biosensor
microplates were obtained from Corning Inc.
Receptor Internalization Assays. HT29 cells were plated on an
8-well chamber slide (Nalge Nunc International, Rochester, NY, USA)
with a seeding density of 10000 cells per well and incubated at 37 C for
24 h. Next day, cells were stimulated with a compound or equal amount
of DMSO at 37 C for 1 h. Afterward, cells were fixed with 4%
formaldehyde in 1  PBS for 15 min, followed by blocking and
permeabilization in a buffer containing 4% goat serum, 0.1% bovine
serumalbumin(BSA),0.1%TritonX100in1 PBSfor2h.After5min
wash with PBS, fixed cells were incubated with the anti-GPR35 (1:500)
(anti-GPR35, T-14, intracellular domain) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) in 3% BSA/PBS buffer for 24 h, followed by
incubation with secondary antibody Alexa Fluor 594 donkey antigoat
IgG (H + L) (1:500) (Invitrogen) in 3% BSA/PBS for 1 h at room
temperature. Cells were finally washed once with PBS and sealed with
1.5 mm thick glass coverslip (Corning, NY). Dried slides were stored at
4Cuntilimaging.ConfocalimagingwasperformedwithZeissconfocal
microscope Axiovert 40. The collected images were analyzed using
MacBiophotonics Image J software (http://www.macbiophotonics.ca/
downloads.htm).
Western Blotting. Transfection of shRNA constructs were per-
formed in 6-well tissue culture treated plate (Corning) with Effectene
transfection system according to manufacturer’s instructions (Qiagen).
Two days following transfection, cells were washed with PBS once and
lysed with NP40 lysis buffer (Invitrogen) containing 1  protease
inhibitor cocktail (Fisher Scientific) and the whole cell lysate was
harvested and centrifuged at 20000 rpm for20 minat 4C.Supernatant
(cytoplasmic fraction) of the cell lysate was collected and subjected to
BCA assay (Sigma Aldrich, St. Louis, MO, USA) to determine the
protein concentration. Then 100 μg of cytoplasmic fraction of cell
lysates were subjected to electrophoresis in 10  Nu-PAGE gel
(Invitrogen), followed by being transferred to HyBond PDVF mem-
brane (GE Healthcare Life Science, Piscataway, NJ, USA). For blotting,
the protein membrane was blocked with 5% milk in TBST (0.05%
Tween) and then incubated with anti-GPR35 (1:500) (Santa Cruz) for
overnight at 4 C. Next day, the membrane was washed with PBS for
3 times with 10 min each and incubated with antirabbit IgG conjugated
horseradish peroxidase for 1 h at room temperature, followed by
enhanced chemiluminescence detection with ECL plus (GE Healthcare
Life Science). Equivalent gel loading was confirmed by probing with β-
actin antibody (Santa Cruz).
Tango β-Arrestin Translocation Gene Reporter Assays.
Tango GPR35-bla U2OS cells was used. This cell line stably expresses
two fusion proteins: human GPR35 linked to a TEV protease site and a
Gal4-VP16 transcription factor and β-arrestin/TEV protease fusion
protein. The cell line also stably expresses the β-lactamase reporter
gene under the control of a UAS response element. The activation of
GPR35 by agonists leads to the recruitment of β-arrestin/TEV protease
fusion proteins to the activated GPR35. As a result, the protease cleaves
the Gal4-VP16 transcription factor from the receptor, which then
translocates to the nucleus and activates the expression of β-lactamase.
Briefly, 10000 cells per well were seeded in 384-well, black-wall, clear-
bottom assay plates with low fluorescence background (Corning)
and cultured in Dulbecco’s Modified Eagle Medium (Invitrogen,
10569 010) supplemented with 10% dialyzed fetal bovine serum,
0.1 μM nonessential amino acids, 25 μM Hepes (pH 7.3), 100 U/mL
penicillin, and 100 μg/mL streptomycin. After overnight culture, the
cellswerestimulatedwithligandsfor5hinahumidified37C/5%CO2
and then loaded with the cell permeable LiveBLAzer FRET B/G
substrate. After the 2 h incubation, the coumarin:fluorescein ratio
was measured using Tecan Safire II microplate reader (M€ annedorf,
Switzerland). In the absence of β-lactamase expression (i.e., no GPR35
activation), cells generated green fluorescence. In the presence of β-
lactamaseexpressionuponreceptoractivation,thesubstratewascleaved
and the cells generated blue fluorescence. The coumarin:fluorescein
ratio was used as a normalized reporter response.
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